ALDX - Abbvie extends option agreement with Aldeyra for dry eye candidate
2023-12-21 17:12:11 ET
More on AbbVie, Aldeyra Therapeutics
- AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition
- AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time
- AbbVie: $10 Billion Cancer Deal To Boost Growth
- Aldeyra stock jumps 8% on dermatitis drug updates
- AbbVie, AstraZeneca targeted for improper use of drug patents
For further details see:
Abbvie extends option agreement with Aldeyra for dry eye candidate